Hims & Hers Health/$HIMS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Hims & Hers Health
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Ticker
$HIMS
Sector
Primary listing
NYSE
Employees
1,637
Headquarters
Website
HIMS Metrics
BasicAdvanced
$11B
60.53
$0.78
2.14
-
Price and volume
Market cap
$11B
Beta
2.14
52-week high
$72.98
52-week low
$18.33
Average daily volume
31M
Financial strength
Current ratio
4.979
Quick ratio
4.205
Long term debt to equity
185.047
Total debt to equity
185.604
Interest coverage (TTM)
112.13%
Profitability
EBITDA (TTM)
160.154
Gross margin (TTM)
76.20%
Net profit margin (TTM)
9.62%
Operating margin (TTM)
6.50%
Effective tax rate (TTM)
-39.05%
Revenue per employee (TTM)
$1,230,000
Management effectiveness
Return on assets (TTM)
6.95%
Return on equity (TTM)
41.88%
Valuation
Price to earnings (TTM)
60.528
Price to revenue (TTM)
5.198
Price to book
19.04
Price to tangible book (TTM)
26.5
Price to free cash flow (TTM)
87.574
Free cash flow yield (TTM)
1.14%
Free cash flow per share (TTM)
0.542
Growth
Revenue change (TTM)
88.69%
Earnings per share change (TTM)
866.21%
3-year revenue growth (CAGR)
75.30%
3-year earnings per share growth (CAGR)
24.05%
What the Analysts think about HIMS
Analyst ratings (Buy, Hold, Sell) for Hims & Hers Health stock.
Bulls say / Bears say
Hims & Hers plans to offer Eli Lilly's Zepbound (tirzepatide) and generic versions of liraglutide, expanding its weight-loss lineup as regulations tighten on compounding. (Reuters)
In Q1 2025, Hims & Hers posted 111% year-over-year revenue growth, with GLP-1 weight-loss drug sales making up $200 million of its $1.5 billion 2024 revenue, highlighting strong demand. (Reuters)
On September 10, 2025, Hims & Hers launched personalized low testosterone treatments and plans to roll out Kyzatrex and injectable therapies in 2026, marking a strategic expansion into men's health. (Reuters)
On June 23, 2025, Novo Nordisk ended its Wegovy distribution partnership with Hims & Hers, leading HIMS shares to fall over 30%, showing the company's exposure to partner disputes. (Reuters)
In May 2025, Hims & Hers reduced its workforce by 4% after the FDA banned compounded weight-loss drug copies, with its shares dropping 14%, underscoring regulatory risks. (Reuters)
Analysts have raised concerns about the legitimacy of Hims & Hers' "personalized" semaglutide dosages and warn that ongoing compounding could trigger legal issues and limit insurer partnerships. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.
HIMS Financial Performance
Revenues and expenses
HIMS Earnings Performance
Company profitability
HIMS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Hims & Hers Health stock?
Hims & Hers Health (HIMS) has a market cap of $11B as of October 24, 2025.
What is the P/E ratio for Hims & Hers Health stock?
The price to earnings (P/E) ratio for Hims & Hers Health (HIMS) stock is 60.53 as of October 24, 2025.
Does Hims & Hers Health stock pay dividends?
No, Hims & Hers Health (HIMS) stock does not pay dividends to its shareholders as of October 24, 2025.
When is the next Hims & Hers Health dividend payment date?
Hims & Hers Health (HIMS) stock does not pay dividends to its shareholders.
What is the beta indicator for Hims & Hers Health?
Hims & Hers Health (HIMS) has a beta rating of 2.14. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.